Modes of action of drugs related to narcolepsy: Pharmacology of wake-promoting compounds and anticataplectics

Narcolepsy: A Clinical Guide

Volumn , Issue , 2010, Pages 267-286

  Nishino, Seiji ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamine; Antidepressants; Cataplexy; Gamma hydroxybutyrate; Modafinil; Narcolepsy; Stimulants

Indexed keywords

EID: 80755180301     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0854-4_24     Document Type: Chapter

References (92)

1. Jones BE. Basic mechanism of sleep-wake states. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine 4th ed. Philadelphia: Elsevier Saunders; 2005:136-53.
2. Jouvet M. The role of monoamines and acetylcholine-con-taining neurons in the regulation of the sleep-waking cycle. Ergeb Physiol 1972;64:166-307.
3. Nishino S, Mignot E, Dement WC. Sedative-hypnotics. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psycho-pharmacology. 2 ed. Washington: American Psychiatric Press; 2004:651-84.
4. Steinfels GF, Heym J, Streckjer RE, Jacobs BJ. Behavioral correlates of dopaminergic activity in freely moving cats. Brain Res 1983;258:217-28.
5. Björklund A, Lindvall O. Dopamine-containing systems in the CNS. In: Björklund A, Hökfelt T, eds. Handbook of Chemical Neuroanatomy, Vol 2, Classical Transmitter in the CNS, Part I. Amsterdam: Elsevier; 1984:55-121.
6. Trulson ME. Simultaneous recording of substantia nigra neurons and voltammetric release of dopamine in the caudate of behaving cats. Brain Res Bull 1985;15:221-3.
7. Ljungberg T, Apicella P, Schultz W. Responses of monkey dopamine neurons during learning of behavioral reactions. J Neurophysiol 1992;67(1):145-63.
8. Jones BE, Bobillier P, Pin C, Jouvet M. The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat. Brain Res 1973;58:157-77.
9. Lu J, Jhou TC, Saper CB. Identifcation of wake-active dop-aminergic neurons in the ventral periaqueductal gray matter. J Neurosci 2006;26(1):193-202.
10. Moller JC, Stiasny K, Cassel W, Peter JH, Kruger HP, Oertel WH. ["Sleep attacks" in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists?]. Nervenarzt 2000;71(8):670-6.
11. Hartmann A, Cravens J. Sleep: effect of d-and l-amphet-amine in man and rat. Psychopharmacology 1976;50:171-5.
12. Kuczenski R, Segal DS. Neurochemistry of amphetamine. In: Cho AK, Segel DS, eds. Psychopharmacology, Toxicology and Abuse. San Diego: Academic; 1994:81-113.
13. Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A. Amphetamine-induced dopamine effux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem 2003;278(14):12070-7.
14. Segal DS, Kuczenski R. Behavioral pharmacology of amphetamine. In: Cho AK, Segal DS, eds. Amphetamine and its Analogs: Psychopharmacology, Toxicology and Abuse. San Diego: Academic; 1994:115-50.
15. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52(1):27-78.
16. Parkes JD, Baraitser M, Marsden CD, Asselman P. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand 1975;52:337-53.
17. Nishino S, Mao J, Sampathkumaran R, Shelton J, Mignot E. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998;1:49-61. http://www.sro.org/1998/Nishino/49/.
18. Kanbayashi T, Nishino S, Honda K, Shelton J, Dement WC, Mignot E. Differential effects of D-and L-amphetamine isomers on dopaminergic transmission: implication for the control of alertness in canine narcolepsy. Sleep Res 1997;26:383.
19. Kuczenski R, Segal DS, Cho A, Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 1995;15:1308-17.
20. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21(5):1787-94.
21. Xu F, Gainetdinov RR, Wetsel WC, et al. Mice lacking the norepinephrine transporter are supersensitive to psychostim-ulants. Nat Neurosci 2000;3(5):465-71.
22. Honda K, Riehl J, Mignot E, Nishino S. Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep. Neuroreport 1999;10(17):3717-24.
23. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafnil binds to the dopamine uptake carrier site with low affnity. Sleep 1994;17:436-7.
24. NuvigilTM (armodafnil) Tablets prescribing information. (Accessed at http://www.cephalon.com/newsroom/assets/nuvigil-prescribing-information.pdf)
25. Tanganelli S, Fuxe K, Ferraro L, Jansen AM. Inhibitory effects of the psychoactive drug modafnil on gamma-aminobutyric acid outfow from the cerebral cortex of the awake freely moving guinea pig. Arch Pharmacol 1992;345:461-5.
26. Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M. Role of catecholamines in modafnil and amphetamine induced wakefulness, a comparative pharmacological study. Brain Res 1992;591:319-26.
27. Ferraro L, Tananelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K. The vigilance promoting drug modafnil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996;306:33-9.
28. Duteil J, Rambert FA, Pessonnier J, Hermant J, Gombert R, Assous E. Central a1-adrenergic stimulation in relation to the behaviour stimulating effect of modafnil: studies with experimental animals. Eur J Pharmacol 1990;180:49-58.
29. Minzenberg MJ, Carter CS. Modafnil: a review of neuro-chemical actions and effects on cognition. Neuropsy-chopharmacology 2008;33(7):1477-502.
30. Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK. Modafnil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 2007;568(1-3):112-23.
31. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafnil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995;18:817-26.
32. Nishino S, Fruhstorfer B, Arrigoni J, Guilleminault C, Dement WC, Mignot E. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther 1993;264:1079-84.
33. Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafnil. Neuroscience 2005;132(4):1027-34.
34. Parmentier R, Anaclet C, Guhennec C, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 2007;73(8):1157-71.
35. Korotkova TM, Klyuch BP, Ponomarenko AA, Lin JS, Haas HL, Sergeeva OA. Modafnil inhibits rat midbrain dopamin-ergic neurons through D2-like receptors. Neuropharmacology 2007;52(2):626-33.
36. Nissbrandt N, Engberg G, Pileblad E. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra. Naunyn-Schmiedebergs Arch Pharmacol 1991;344:16-28.
37. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995;15(3):1714-23.
38. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafnil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cats. Proc Natl Acad Sci USA 1996;93:14128-33.
39. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51.
40. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypo-halamic arousal regions are activated during modafnil-induced wakefulness. J Neurosci 2000;20(22):8620-8.
41. Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A. Modafnil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 2003;339(2):143-6.
42. Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P. Effect of the wake-promoting agent modafnil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004;27(1):19-25.
43. Madras BK, Xie Z, Lin Z, et al. Modafnil occupies dop-amine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006;319(2):561-9.
44. Nishino S, Okuro M. Armodafnil for excessive daytime sleepiness. Drugs Today (Barc) 2008;44(6):395-414.
45. Iijima S, Sugita Y, Teshima Y, Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 1986;9(1):265-8.
46. Nishino S, Mao J, Sampathkumaran R, Shelton J, Dement WC, Mignot E. Adrenergic, but not dopaminergic, uptake inhibition reduces REM sleep and cataplexy concomitantly. Sleep Res 1997;26:445.
47. Radulovacki M, Virus RM, Djuricic-Nedelson M, Green RD. Adenosine analogs and sleep in rats. J Pharmacol Exp Ther 1984;228(2):268-74.
48. Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997;276(5316):1265-8.
49. Huang ZL, Qu WM, Eguchi N, et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 2005;8(7):858-9.
50. Siegel JM. Brainstem mechanisms generating REM sleep. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. Philadelphia: W. B. Saunders Company; 2000:112-33.
51. Nishino S, Taheri S, Black J, Nofzinger E, Mignot E. The neurobiology of sleep in relation to mental illness. In: Charney DS NE, ed. Neurobiology of Mental Illness. New York: Oxford University Press; 2004:1160-79.
52. Wu MF, Gulyani SA, Yau E, Mignot E, Phan B, Siegel JM. Locus coeruleus neurons: cessation of activity during cata-plexy. Neuroscience 1999;91(4):1389-99.
53. John J, Wu MF, Boehmer LN, Siegel JM. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 2004;42(4):619-34.
54. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using mono-amine selective uptake inhibitors and release enhancers. Psychopharmacology 1993;113(1):76-82.
55. Peet M, Coppen A. The pharmacokinetics of antidepressant drugs: relevance to their therapeutic effect. In: Paykel ES, Coppen A, eds. Psychopharmacology of Affective Disorders. Oxford: Oxford University Press; 1979:91-107.
56. Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993;16(8):706-12.
57. Baker TL, Dement WC. Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholin-ergic imbalance. In: McGinty DJ, Drucker-Colin R, Morrison A, Parmeggiani PL, eds. Brain Mechanisms of Sleep. New York: Raven; 1985:199-233.
58. Wu MF, John J, Boehmer LN, Yau D, Nguyen GB, Siegel JM. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J Physiol 2004;554(Pt 1):202-15.
59. Nishino S, Haak L, Shepherd H, et al. Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep. J Pharmacol Exp Ther 1990;253:1145-52.
60. Nishino S, Arrigoni J, Valtier D, et al. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci 1991;11:2666-71.
61. Reid MS, Tafti M, Nishino S, et al. Local administration of dopaminergic drugs into the ventral tegmental area modulate cataplexy in the narcoleptic canine. Brain Res 1996; 733:83-100.
62. Okura M, Riehl J, Mignot E, Nishino S. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology 2000;23(5):528-38.
63. Okura M, Fujiki N, Ripley B, et al. Narcoleptic canines display periodic leg movements during sleep. Psychiatry Clin Neurosci 2001;55(3):243-4.
64. Okura M, Fujiki N, Kita I, et al. The roles of midbrain and diencephalic dopamine cell groups in the regulation of cata-plexy in narcoleptic Dobermans. Neurobiol Dis 2004; 16(1):274-82.
65. Wyatt RJ, Fram DH, Buchbinder R, Snyder F. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med 1971;285(18):987-91.
66. Gillin JC, Horwitz D, Wyatt RJ. Pharmacologic studies of narcolepsy involving serotonin, acetylcholine, and mono-amine oxidase. In: Guilleminault C, Dement WC, Passouant P, eds. Narcolepsy (Advances in Sleep Research Vo l 3). New York: Spectrum Publications; 1976:585-603.
67. Krishnan KRR. Monoamine oxidase inhibitors. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psycho-pharmacology. 2 ed. Washington: American Psychiatric Press; 2004:303-14.
68. Ranga K, Krishnan R. Monoamine oxidase inhibitors. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psycho-pharmacology. Washington: American Psychiatric Press; 1994:183-93.
69. Hohagen F, Mayer G, Memche A, et al. Treatment of narco-lepsy-cataplexy syndrome with the new selective and reversible mao-a inhibitor brofaromine-a pilot study. J Sleep Res 1993;2:250-6.
70. Hublin C, Partinen M, Heinonen EH, Puukka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology 1994;44(11):2095-101.
71. Nishino S, Arrigoni J, Kanbayashi T, Dement WC, Mignot E. Comparative effects of MAO-A and MAO-B selective inhibitors on canine cataplexy. Sleep Res 1996;25:315.
72. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979;6(1):1-6.
73. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with g-hydroxybutyrate. A review of clinical and sleep laboratory fndings. Sleep 1986;9(1):285-9.
74. Group USXMS. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25(1):42-9.
75. Group UXMS. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26(1):31-5.
76. Group UXMS. Sodium oxybate demonstrates long-term effcacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5(2):119-23.
77. Group UXMS. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1(4):391-7.
78. Laborit H, Buchard F, Laborit G, Kind A, Weber B. [Use of sodium 4-hydroxybutyrate in anesthesia and resuscitation.]. Agressologie 1960;1:549-60.
79. Bessman SP, Fishbein WN. Gamma-hydroxybutyrate, a normal brain metabolite. Nature 1963;200:1207-8.
80. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997;51(3):337-61.
81. Snead OC, 3rd. The ontogeny of [3H]gamma-hydroxybu-tyrate and [3H]GABAB binding sites: relation to the development of experimental absence seizures. Brain Res 1994; 659(1-2):147-56.
82. Castelli MP, Mocci I, Langlois X, et al. Quantitative autora-diographic distribution of gamma-hydroxybutyric acid binding sites in human and monkey brain. Brain Res Mol Brain Res 2000;78(1-2):91-9.
83. Wong CG, Gibson KM, Snead OC, 3rd. From the street to the brain: neurobiology of the recreational drug gamma-hydroxy-butyric acid. Trends Pharmacol Sci 2004;25(1):29-34.
84. Crunelli V, Leresche N. Childhood absence epilepsy: genes, channels, neurons and networks. Nat Rev Neurosci 2002; 3(5):371-82.
85. Poldrugo F, Addolorato G. The role of gamma-hydroxybu-tyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol 1999;34(1):15-24.
86. Castelli MP, Pibiri F, Carboni G, Piras AP. A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor. CNS Drug Rev 2004;10(3):243-60.
87. Andriamampandry C, Taleb O, Viry S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J 2003;17(12):1691-3.
88. Kemmel V, Taleb O, Perard A, et al. Neurochemical and electrophysiological evidence for the existence of a functional gamma-hydroxybutyrate system in NCB-20 neurons. Neuroscience 1998;86(3):989-1000.
89. Kemmel V, Taleb O, Andriamampandry C, Aunis D, Maitre M. Gamma-hydroxybutyrate receptor function determined by stimulation of rubidium and calcium movements from NCB-20 neurons. Neuroscience 2003;116(4):1021-31.
90. American Narcolepsy Association. Stimulant medication survey. Eye Opener 1992;5:1-3.
91. Kanbayashi T, Honda K, Kodama T, Mignot E, Nishino S. Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D-and L-derivatives in canine narcolepsy. Neuroscience 2000; 99(4):651-9.
92. Wong CG, Chan KF, Gibson KM, Snead OC. Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev 2004;23(1):3-20.